Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$29.89 – $35.06
85% from low
Exchange
ARCX
ETF
Borrow rate
9.74%
Hard to borrow
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| CAMXCambiar Aggressive Value ETF | $34.35 | -0.25% | $67M | — |
| AIVIWisdomTree International AI Enhanced Value Fund | $56.09 | +0.36% | $64M | — |
| BIBProShares Ultra Nasdaq Biotechnology | $100.48 | +2.24% | $82M | — |
| BKSEBNY Mellon US Small Cap Core Equity ETF | $132.98 | -0.80% | $83M | — |
| BLCViShares Large Cap Value Active ETF | $39.56 |
No company description on file.
No one on the platform currently holds CAMX.
No tracked institution reports a position in CAMX as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-30 | $0.4793 | 2026-01-07 |
| 2025-09-25 | $0.0914 | 2025-09-26 |
| 2024-12-30 | $0.3884 | 2025-01-07 |
| 2023-12-28 | $0.1464 | 2024-01-05 |
No one on the platform has traded CAMX yet.
| +0.69% |
| $113M |
| — |
| EASGXtrackers MSCI EAFE Selection Equity ETF | $38.35 | +1.49% | $70M | — |
| FLEUFranklin FTSE Eurozone ETF | $35.28 | +0.20% | $71M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Camurus ($CAMX) scores a CHMP recommendation for Oczyesa in acromegaly – a major step toward EU approval. With superior efficacy vs. placebo and a patient-friendly monthly self-injection, this could disrupt the standard of care. Final EC decision expected imminently. High stakes for a rare disease market. https://www.prnewswire.com/news-releases/chmp-recommends-approval-of-oczyesa-for-treatment-of-acromegaly-in-the-eu-302438435.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.